[1] Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci,2013,58:326-343.
[2] Nicole MF,Gerven V,Bart J,et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol,2014,49（10）:1245-1254.
[3] Trivedi PJ,Hirschfield GM. Treatment of autoimmune liver disease:current and future therapeutic options. Ther Adv Chronic Dis,2013,4:119-141.
[4] Krawitt EL. Autoimmune hepatitis. N Engl J Med,2006,354（1）:54-66.
[5] Dalekos GN,Zachou K,Liaskos C,et al. Autoantibodies and defined target autoantigens in autoimmune hepatitis:an overview. Eur J Intern Med,2002,13（5）:293-303
[6] Kanno Y,Watanabe H,Takahashi A,et al. Anti-phosphoenolpyruvate 2 antibody in patients with autoimmune hepatitis. Hepatol Res,2014,44（9）:1019-1025.
[7] Tan L,Zhang Y,Peng W,et al. Detection of anti-lactoferrin antibodies and anti-myeloperoxidase antibodies in autoimmunehepatitis:a retrospective study. J Immunoassay Immunochem,2014,35（4）:388-397.
[8] Miao Q,Bian Z,Tang R,et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin Rev Allergy Immunol. 2014,23:567-577.
[9] Boer YS,van Nieuwkerk CM,Witte BI,et al. The assessment of the histopathological key-features in autoimmune hepatitis. Histopathology,2014,26:111-125.
[10] Wang JB,Pu SB,Sun Y,et al. Metabolomic proliling of autoimmune hepatitis:The diagnostic utility of nuclear magnetic resonance spectroscopy. J Proteome Res,2014,13:3792-3801.
[11] Vergani D,Alvarez F,Bianchi FB,et al. Liver autoimmune serology:a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol,2004,41:677-683.
[12] Czaja AJ,Manns MP,McFarlane IG,et al. Autoimmune hepatitis:the investigational and clinical challenges. Hepatology,2000,31（5）:1194-1200.
[13] Alvarez F,Berg PA,Bianchi FB,et al. International Autoimmune Hepatitis Group Report:review of criteria for diagnosis of autoimmune hepatitis. J Hepatol,1999,31（5）:929-938.
[14] Hennes EM,Zeniya M,Czaja AJ,et al. Simplified criteria for the diagnosis of autoimmune hepatitis.Hepatology,2008,48（1）:169-176.
[15] Dekai Q,Qixia W,Hui W. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol,2011. 54:340-347.
[16] 贾继东.进一步提高自身免疫性肝脏疾病的诊疗水平. 中华肝脏病杂志,2010,18（5）：321-322.
[17] Wang QX,Jiang WJ,Miao Q,Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients: A single center experience. J Dig Dis,2013,14:175-180.
[18] Wang Q,Qiu D,Ma X. Early normalisation of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients. Aliment Pharmacol Ther,2011,34（1）:107-109.
[19] Taubert R,Hardtke-Wolenski M,Noyan F,et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol,2014,61（5）:1106-1114.
[20] Weiler-Normann C,Schramm C,Quaas A,et al. Infiximab as a rescue treatment in diffcult-to-treat autoimmune hepatitis. J Hepatol,2013,58:529-534.
[21] Longhi MS,Hussain MJ,Kwok WW,et al. Autoantigen-specific regulatory T cells,a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology,2011,53:536-547.
[22] Andrew D,Yeoman,Rachel H,et al. Prognosis of acute severe autoimmune hepatitis（AS-AIH）:The role of corticosteroids in modifying outcome. Hepatology,2014,61:876-882.
[23] Invernizzi P. Geoepidemiology of autoimmune liver diseases. J Autoimmun,2010,34（3）:300-306.
[24] European Association for the study of the liver.EASL Clinical Practice Guidelines:management of cholestatic liver diseases. J Hepatol,2009,51（2）:237-267.
[25] Hu SL,Zhao FR,Hu Q,et al. Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis. PLoS One,2014,9（7）:1916-1925.
[26] Hu S,Zhao F,Wang Q,et al. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis:a meta-analysis. Clin Chem Lab Med,2014,2:1015-1026.
[27] Ma DX, Li X, Zhang L, et al. S100A12 expression in patients with primary biliary cirrhosis. Immunoll Investig,2014,10:1532-1542.
[28] Norman1 GL,Yang CY,Heather P,et al. Anti-kelch-like 12 and anti-hexokinase 1:novel autoantibodies in primary biliary cirrhosis. Liver Int,2014,10 :1-10.
[29] Hiroto T,Hiromasa O,Hiromitsu A,et al. Anti-M3 muscarinic acetylcholine receptor antibodies in patients with primary biliary cirrhosis. Hepatol Res,2014,4:1111-1129.
[30] Li YJ,Tang YW,Shi YQ,et al. Polymorphisms in the vitamin D receptor gene and risk of primary biliary cirrhosis:A meta-analysis. J Gastroenterol Hepatol,2014,29:706-715.
[31] Bioulac-Sage P. Primary biliary cirrhosis:a new histological staging and grading system proposed by Japanese authors. Clin Res Hepatol Gastroenterol,2011,35:333-335.
[32] Chan AW,Chan RC,Wong GL,et al. Evaluation of histological staging systems for primary biliary cirrhosis:correlation with clinical and biochemical factors and signifcance of pathological parameters in prognostication. Histopathology,2014,31:174-186.
[33] Dominique W,Pierre-Y,Pierre B,et al. Primary biliary cirrhosis-proposal for a new simple histological scoring system. Liver Int,2014,10:32-42
[34] Tan Y,Pan T,Ye Y,et al. Serum MicroRNAs as potential biomarkers of primary biliary cirrhosis. PLoS One,2014,10:1424-1430.
[35] Zhang D,Chen M,Liu Y,et al. Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis: A preliminary study. Clin Radiol,2014,69:836-840.
[36] Xiao FH,Qi XW,Yuan L,et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis,2012,13:219-224.
[37] Lens S,Leoz M,Nazal L,et al. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int,2014,34:197-203.
[38] Silveira MG,Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother,2014,15:365-372.
[39] Nevens F,Andreone P,Mazzella G,et al. The first primary biliary cirrhosis phase 3 trial in two decades-an international study of the FXR agonist obeticholic acid in PBC patients. J Hepatol,2014,60:525-526.
[40] Wang L,Han Q,Chen H,et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells,2014,23（20）:2482-2489.
[41] Mayer L,Sandborn WJ,Stepanov Y,et al. Anti-IP-10 antibody（BMS-936557） for ulcerative colitis:a phase II randomisedstudy. Gut,2014,63:442-450.
[42] Tanaka H,Zhang W,Yang GX,et al. Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3（+） regulatory T cells. Clin Exp Immunol,2014,178（2）:253-261.
[43] Kate D,Williamson H,Roger W,et al. Primary sclerosing cholangitis. Dig Dis,2014,32:438-445. |
